Insurance Denied Immunotherapy? How to Appeal Checkpoint Inhibitor Denials
Immunotherapy denials for pembrolizumab, nivolumab, and other checkpoint inhibitors often hinge on on-label vs. off-label distinctions. Learn how NCCN Compendium and FDA designations support your appeal.
Insurance Denied Immunotherapy? How to Appeal Checkpoint Inhibitor Denials
Checkpoint inhibitors — including pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), and ipilimumab (Yervoy) — have transformed cancer treatment. These immunotherapy drugs have demonstrated survival benefits across a growing range of tumor types. Yet insurance denials for immunotherapy remain common, often resting on narrow label interpretations or outdated coverage policies. Here's how to fight back.
Why Insurers Deny Immunotherapy
"Off-label use not covered" — The drug is FDA-approved for cancer treatment but your specific tumor type or biomarker profile is not listed in the current FDA label.
"Not medically necessary" — Insurer's clinical criteria don't recognize the indication even when supported by NCCN guidelines.
"Biomarker threshold not met" — For PD-L1 targeted drugs, insurer requires a specific PD-L1 expression threshold or MSI-H/dMMR status that may not match clinical reality.
"Sequence of therapy requirement" — Insurer requires chemotherapy to be tried before immunotherapy, even when immunotherapy is now first-line standard of care.
"Clinical trial required" — Insurer suggests enrolling in a trial rather than receiving commercial immunotherapy.
On-Label vs. Off-Label Immunotherapy
On-label use: The drug is prescribed for a tumor type and line of therapy explicitly in the FDA-approved prescribing information. This should be covered without dispute.
Off-label use: The drug is used for a tumor type, biomarker profile, or line of therapy not explicitly in the FDA label but supported by published clinical evidence. This is where most coverage battles occur.
Many states and federal laws require coverage of off-label oncology drugs when supported by recognized drug compendia. Federal law (Section 1861 of the Social Security Act, as interpreted by CMS) and many state statutes require coverage when use is supported by:
- NCCN Drugs and Biologics Compendium — the gold standard reference for off-label oncology coverage
- DrugDex (Micromedex) compendium
- AHFSfirst (AHFS Drug Information) compendium
- Clinical pharmacology databases recognized by your state
NCCN Compendium: Your Most Powerful Tool
The NCCN Compendium lists specific drugs, indications, biomarkers, and NCCN evidence categories for oncology drugs. Even when a use is off-label by FDA standards, NCCN Compendium listing creates a legal and contractual obligation to cover it in many states and under Medicare Part B.
For checkpoint inhibitors specifically, look for:
- Category 1 listings: Highest level of NCCN evidence; uniform consensus based on high-quality evidence
- Category 2A listings: Uniform consensus based on lower-level evidence — still broadly accepted for coverage purposes
- The specific tumor type, histology, and biomarker (e.g., PD-L1 expression ≥1%, MSI-H, TMB-H, NTRK fusion)
Your oncologist should be able to pull the specific NCCN entry for your tumor type and the proposed immunotherapy agent and include it in the appeal letter.
FDA Breakthrough Designations and Accelerated Approvals
Even when formal FDA approval is pending, FDA Breakthrough Therapy Designation and Accelerated Approval status can support coverage arguments:
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →
- Breakthrough Therapy Designation signals FDA recognition that the drug may represent substantial improvement over existing therapy — this is a meaningful clinical signal
- Accelerated Approval means the drug is already FDA-approved based on surrogate endpoints pending confirmatory trial data — it is not experimental
- Many checkpoint inhibitors received Accelerated Approval based on ORR (objective response rate) data, with full approval later confirmed
If your drug has any form of FDA recognition, document it explicitly in your appeal.
Tumor-Agnostic Approvals
Several checkpoint inhibitors now hold tumor-agnostic FDA approvals based on biomarkers rather than tumor type:
- Pembrolizumab (Keytruda): FDA-approved for any solid tumor that is MSI-H/dMMR (mismatch repair deficient), TMB-H (tumor mutational burden ≥10 mut/Mb), or NTRK fusion-positive
- Dostarlimab (Jemperli): Approved for dMMR solid tumors
- Larotrectinib and entrectinib: Approved for NTRK gene fusion-positive solid tumors
If your tumor carries one of these biomarkers, the use is on-label regardless of tumor type. Include your biomarker testing results (NGS/genomic profiling) in your appeal documentation.
Sequence of Therapy Disputes
Some insurers require chemotherapy before immunotherapy — even when immunotherapy is now recognized as first-line standard of care. For example:
- Pembrolizumab monotherapy is first-line for non-small cell lung cancer with PD-L1 ≥50% — NCCN Category 1
- Nivolumab plus ipilimumab is first-line for MSI-H colorectal cancer — NCCN Category 1
- Pembrolizumab is first-line for classical Hodgkin lymphoma in relapsed/refractory settings
When immunotherapy is the current first-line standard per NCCN, a requirement to try chemotherapy first is not consistent with the standard of care. Challenge the sequence requirement directly by citing the specific NCCN recommendation.
Step-by-Step Immunotherapy Appeal
Step 1: Determine whether the use is on-label or off-label and why the insurer denied.
Step 2: Pull the NCCN Compendium entry for your tumor type and the specific drug — have your oncologist provide this directly.
Step 3: Document your tumor's biomarker profile (PD-L1, MSI/MMR, TMB, NTRK, etc.) with lab reports.
Step 4: Cite applicable state laws or Medicare regulations requiring coverage of off-label oncology use supported by recognized compendia.
Step 5: Address any sequence-of-therapy requirements by citing the NCCN first-line designation if applicable.
Step 6: Request peer-to-peer review between your oncologist and the insurer's medical director.
Step 7: File the internal appeal. For life-threatening conditions, request expedited appeal (typically 72 hours). If denied, request external IMR with an oncology reviewer.
Fight Back With ClaimBack
Immunotherapy denials are among the most consequential insurance decisions patients face — and among the most frequently overturned when properly challenged with NCCN and FDA citations. ClaimBack guides you through every step of the appeal process.
Start your immunotherapy appeal at ClaimBack
Related Reading
How much did your insurer deny?
Enter your denied claim amount to see what you could recover.
Your insurer is counting on you giving up.
Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.
We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.
Free analysis · No credit card · Takes 3 minutes
Related ClaimBack Guides